Effects and mechanisms of actions of Chinese herbal medicines for asthma

Min-li Hong; Ying Song; Xiu-min Li

doi:10.1007/s11655-011-0780-5

Your Location：

Home >

Browse articles >

Effects and mechanisms of actions of Chinese herbal medicines for asthma

OriginalPaper | Updated：2021-08-27

- Effects and mechanisms of actions of Chinese herbal medicines for asthma
- Effects and mechanisms of actions of Chinese herbal medicines for asthma
- 中国结合医学杂志（英文版） 2011年17卷第7期页码：483-491
- Affiliations：
  
  1. Center for Chinese Medicine for Allergy and Asthma, Jaffe Food Allergy Institute, Pediatric Department, Division of Allergy and Immunology, The Mount Sinai School of Medicine,New York,USA
  2. Respiratory Department, Zhangzhou Traditional Chinese Medicine Hospital, Affiliated Hospital of Fujian University of Traditional Chinese Medicine,Zhangzhou,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-011-0780-5
  中图分类号：
- 纸质出版日期：2011，
  
  网络出版日期：2011-7-3，
Scan for full text
Hong, Ml., Song, Y. & Li, Xm. Effects and mechanisms of actions of Chinese herbal medicines for asthma., Chin. J. Integr. Med. 17, 483–491 (2011). https://doi.org/10.1007/s11655-011-0780-5

Min-li Hong, Ying Song, Xiu-min Li. Effects and mechanisms of actions of Chinese herbal medicines for asthma[J]. Chinese Journal of Integrative Medicine, 2011,17(7):483-491.
Hong, Ml., Song, Y. & Li, Xm. Effects and mechanisms of actions of Chinese herbal medicines for asthma., Chin. J. Integr. Med. 17, 483–491 (2011). https://doi.org/10.1007/s11655-011-0780-5 DOI：

Min-li Hong, Ying Song, Xiu-min Li. Effects and mechanisms of actions of Chinese herbal medicines for asthma[J]. Chinese Journal of Integrative Medicine, 2011,17(7):483-491. DOI： 10.1007/s11655-011-0780-5.

摘要

Asthma is a chronic inflammatory disorder of airways that affects approximately 300 million adults and children worldwide. Most therapy currently uses bronchodilators and corticosteroids. Systemic side effects from chronic use of these drugs are concern. Chinese medicine (CM) has a long history of human use in China and other Asian countries and well received by the patients. But as one component of Western integrative medicine (WIM)

it is required that CM use is supported by scientific evidence. On the other hand

there are also suggestions that Western standardized medicine should consider personalized practice. In recent years there have been an increasing studies to narrow the gap between CM

the personalized medicine and Western medicine

evidence based medicine. This communication reviews several CM studies published in the English language in details by reviewing the effects and mechanisms of actions on asthma from clinic and experimental studies. Chinese herbal medicines exhibit broad actions on multiple asthma pathologic mechanisms. These mechanisms may involve antiinflammatory and immunomodulatory effects

inhibiting airway remodeling and normalization of hypothalamus

pituitary and adrenal (HPA)-axis disturbances. However

the mechanisms of actions of Chinese herbal medicines for asthma are not fully understood. More controlled clinical studies are warranted and some anti-asthma CM may be proved to be effective when used as monotherapy or complementary asthma therapies.

Abstract

it is required that CM use is supported by scientific evidence. On the other hand

there are also suggestions that Western standardized medicine should consider personalized practice. In recent years there have been an increasing studies to narrow the gap between CM

the personalized medicine and Western medicine

inhibiting airway remodeling and normalization of hypothalamus

pituitary and adrenal (HPA)-axis disturbances. However

关键词

Asthmacomplementary and alternative medicineChinese MedicineChinese Herbal Medicinemechanism of action

Keywords

Asthmacomplementary and alternative medicineChinese MedicineChinese Herbal Medicinemechanism of action

references

Dobos G, Tao I. The model of Western integrative medicine: the role of Chinese medicine. Chin J Integr Med 2011;17:11–20.

Bousquet J, Mantzouranis E, Cruz AA, it-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926–938.

CDC. National Center for Health Statistics: Asthma. Available at http://www.cdc.gov/nchs/fastats/asthma.htm [Accessed September 18, 2010].

Liu GL, Lin JT. Overview global epidemiology of asthma. China Medical Tribune (Chin). Available at http://www.cmt.com.cn/newsDetail/104/12009.html. [Accessed April 22, 2010].

Lemanske RFJ. A review of the current guidelines for allergic rhinitis and asthma. J Allergy Clin Immunol 1998;101:S392–S396.

Hall IP. The beta-agonist controversy revisited. Lancet 2004; 363:183–184.

Sheth A, Reddymasu S, Jackson R. Worsening of asthma with systemic corticosteroids. J Gen Intern Med 2006;21:C11–C13.

Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354:1985–1997.

Aun MV, Ribeiro MR, Costa Garcia CL, Agondi RC, Kalil J, Giavina-Bianchi P. Esophageal candidiasis-an adverse effect of inhaled corticosteroids therapy. J Asthma 2009;46:399–401.

Zora JA, Zimmerman D, Carey TL, O’Connell EJ, Yunginger JW. Hypothalamic-pituitary-adrenal axis suppression after short-term, high-dose glucocorticoid therapy in children with asthma. J Allergy Clin Immunol 1986;77(1 Pt 1):9–13.

Saini SS, MacGlashan DW, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999;162:5624–5630.

Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma 2009;46:413–420.

FDA. Early communication about an ongoing safety review of omalizumab (marked as Xolair). Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm172218.htm. FDA. Consum. 9 A.D. [accessed July 16,2009]

Holbrook JT, Harik-Khan R. Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials. J Allergy Clin Immunol 2008;122:828–829.

Li XM, Brown L. Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol 2009;123:297–306.

Wen MC, Wei CH, Hu ZQ, Srivastava K, Ko J, Xi ST, et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol 2005;116:517–524.

Chan CK, Kuo ML, Shen JJ, See LC, Chang HH, Huang JL. Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-responsiveness in stabilized asthmatic children: a randomized, double-blind clinical trial. Pediatr Allergy Immunol 2006;17:316–322.

Chang TT, Huang CC, Hsu CH. Clinical evaluation of the Chinese herbal medicine formula STA-1 in the treatment of allergic asthma. Phytother Res 2006; 20:342–347.

Kelly-Pieper K, Patil SP, Busse P, Yang N, Sampson H, Wisnivesky J, et al. Safety and tolerability of an antiasthma herbal formula (ASHMITM) in adult asthmatics: a randomized, double-blinded, placebo-controlled, dose escalation phase I study. J Altern Complem Med 2009;15:735–743.

Patil SP, W-S Ji, Singha A, Hendricks DE, Busse P, Sampson H, et al. In vitro immunomodulatory effect of ASHMI (anti-asthma herbal medicine intervention) on PBMCs from asthmatics. J Allergy Clin Immunol 2010;125:AB198.

Zhang T, Srivastava K, Wen MC, Yang N, Cao J, Busse P, et al. Pharmacology and immunological actions of a herbal medicine ASHMI on allergic asthma. Phytother Res 2010;24:1047–1055.

Busse PJ, Schofield B, Birmingham N, Yang N, Wen MC, Zhang T, et al. The traditional Chinese herbal formula ASHMI inhibits allergic lung inflammation in antigen-sensitized and antigen-challenged aged mice. Ann Allergy Asthma Immunol 2010;104:236–246.

Srivastava K, Zhang T, Yang N, Sampson H, Li XM. Antiasthma simplified herbal medicine intervention-induced long-lasting tolerance to allergen exposure in an asthma model is interferon-gamma, but not transforming growth factor-beta dependent. Clin Exp Allergy 2010;40:1678–1688.

Srivastava K, Sampson H, Li X. The anti-asthma Chinese herbal formula ASHMI provides more persistent benefits than dexamethasone in a murine asthma model. J Allergy Clin Immun 2011;127:AB261. Ref Type: Abstract.

Nagai T, Arai Y, Emori M, Nunome SY, Yabe T, Takeda T, et al. Anti-allergic activity of a Kampo (Japanese herbal) medicine “Sho-seiryu-to (Xiao-Qing-Long-Tang)” on airway inflammation in a mouse model. Int Immunopharmacol 2004;4:1353–1365.

Nagai T, Nakao M, Shimizu Y, Kodera Y, Oh-Ishi M, Maeda T, et al. Proteomic analysis of anti-inflammatory effects of a Kampo (Japanese Herbal) Medicine ’shoseiryuto (Xiao-Qing-Long-Tang)’ on airway inflammation in a mouse model. Evid Based Complement Alternat Med 2009 Oct 27. [Epub ahead of print]

Chang TT, Huang CC, Hsu CH. Inhibition of mite-induced immunoglobulin E synthesis, airway inflammation, and hyperreactivity by herbal medicine STA-1. Immunopharmacol Immunotoxicol 2006;28:683–695.

Li Y, Wang MY, Fan XS, Qi X, Chen Y, Zhang H et al. Effect of San-ao Decoction, a traditional Chinese prescription, on IL-4 treated normal human bronchial epithelium. J Ethnopharmacol 2010;131:104–109.

Holgate ST, Arshad HS, Roberts GC, Howarth PH, Thurner P, Davies DE. A new look at the pathogenesis of asthma. Clin Sci (Lond) 2010;118:439–450.

Zhao LM, Ma LJ, Zhang LX, Wu JZ. Shenmai Injection inhibiting the extracellular signal regulated kinase-induced human airway smooth muscle proliferation in asthma. Chin J Integr Med 2010;16:331–336.

Chao WW, Kuo YH, Lin BF. Anti-inflammatory activity of new compounds from Andrographis paniculata by NF-kappaB transactivation inhibition. J Agric Food Chem 2010;58:2505–2512.

Pantano C, Ather JL, Alcorn JF, Poynter ME, Brown AL, Guala AS, et al. Nuclear factor-kappaB activation in airway epithelium induces inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2008;177:959–969.

Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009;121:1–13.

Bao Z, Guan S, Cheng C, Wu S, Wong SH, Kemeny DM, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway. Am J Respir Crit Care Med 2009;179:657–665.

Li J, Luo L, Wang X, Liao B, Li G. Inhibition of NF-kappaB 35. expression and allergen-induced airway inflammation in a mouse allergic asthma model by andrographolide. Cell Mol Immunol 2009;6:381–385.

bu-Ghefreh AA, Canatan H, Ezeamuzie CI. In vitro and in vivo anti-inflammatory effects of andrographolide. Int Immunopharmacol 2009;9:313–318.

Wang G, Liu CT, Wang ZL, Yan CL, Luo FM, Wang L, et al. Effects of Astragalus membranaceus in promoting T-helper cell type 1 polarization and interferon-gamma production by up-regulating T-bet expression in patients with asthma. Chin J Integr Med 2006;12:262–267.

Shen HH, Wang K, Li W, Ying YH, Gao GX, Li XB, et al. Astragalus Membranaceus prevents airway hyperreactivity in mice related to Th2 response inhibition. J Ethnopharmacol 2008;116:363–369.

Du Q, Chen Z, Zhou LF, Zhang Q, Huang M, Yin KS. Inhibitory effects of astragaloside IV on ovalbumin-induced chronic experimental asthma. Can J Physiol Pharmacol 2008;86:449–457.

Xiong L, Fang ZY, Tao XN, Bai M, Feng G. Effect and mechanism of ligustrazine on Th1/Th2 cytokines in a rat asthma model. Am J Chin Med 2007;35:1011–1020.

Che XW, Zhang Y, Wang H, Wang W. Effect of ligustrazine injection on levels of interleukin-4 and interferon-gamma in patients with bronchial asthma. Chin J Integr Med 2008;14:217–220.

FULL TEXT LINK

More>

浏览量

941

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Development is a high level inheritance for China Time-honored Brand products

Cancer complementary and alternative medicine research at the US national cancer institute

Fuzheng Huayu Capsule (扶正化瘀胶囊) in the treatment of liver fibrosis: Clinical evidence and mechanism of action

Disease-syndrome combination clinical study of psoriasis: Present status, advantages, and prospects

Chinese medicine for menopausal syndrome: Current status, problems and strategies